Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Published:2023-05 Issue:5 Volume:13 Page:2250-2258
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Xu Binghe,Zhang Qingyuan,Hu Xichun^ORCID,Li Qing,Sun Tao,Li Wei,Ouyang Quchang,Wang Jingfen,Tong Zhongsheng,Yan Min,Li Huiping,Zeng Xiaohua,Shan Changping,Wang Xian,Yan Xi,Zhang Jian,Zhang Yue,Wang Jiani,Zhang Liang,Lin Ying,Feng Jifeng,Chen Qianjun,Huang Jian,Zhang Lu,Yang Lisong,Tian Ying,Shang Hongyan

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference32 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2022

2. Breast cancer—one term, many entities?;Bertos;J Clin Invest,2011

3. Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer;Andrahennadi;Curr Oncol,2021

4. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Senkus;Ann Oncol,2015

5. ESO-ESMO international consensus guidelines for advanced breast cancer (abc 3);Cardoso;Ann Oncol,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospects for breast cancer immunotherapy using microRNAs and transposable elements as objects;Exploration of Targeted Anti-tumor Therapy;2024-08-06

2. The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells;International Journal of Molecular Sciences;2024-08-02

3. Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth;PLOS ONE;2024-07-15

4. Breast cancer epigenetics: current and evolving treatment;Breast Cancer;2024-06-11

5. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors;The Oncologist;2024-05-31